1-6 of 6
William F. Symmans
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P3-01-02: Impact of race, socioeconomic status and clinicopathological features on clinical outcomes in triple negative breast cancer in the ECOG-ACRIN EA1131 trial

Free
Moriah Forster, Fengmin Zhao, Sarah Bell, Ingrid A. Mayer, Carlos L. Arteaga, William F. Symmans, Ben H. Park, Brian L. Burnette, Amye J. Tevaarwerk, Sofia F. Garcia, Karen L. Smith, Della F. Makower, Margaret Block, Kimberly A. Morley, Chirag R. Jani, Craig Mescher, Shabana J. Dewani, Bernard Tawfik, Lisa E. Flaum, Erica L. Mayer, William M. Sikov, Eve T. Rodler, Lynne I. Wagner, Angela M. DeMichele, Joseph A. Sparano, Ruth C. Carlos, Antonio C. Wolff, Kathy D. Miller, Sonya Reid
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-01-02.
https://doi.org/10.1158/1557-3265.SABCS24-P3-01-02
Published: 13 June 2025
View article titled, Abstract P3-01-02: Impact of race, socioeconomic status and clinicopathological features on clinical outcomes in triple negative breast cancer in the ECOG-ACRIN EA1131 trial
Journal Articles

Abstract P2-10-19: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer

Free
Ciara O'Sullivan, Karla V. Ballman, Linda M. McCall, Tyler J. Zemla, Anna C. Weiss, Melissa P. Mitchell, Victoria S. Blinder, Nadine M. Tung, William J. Irvin, Sailaja Kamaraju, Matthew P. Goetz, William F. Symmans, Virginia F. Borges, Ian E. Krop, Ann H. Partridge, Lisa A. Carey
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-10-19.
https://doi.org/10.1158/1557-3265.SABCS24-P2-10-19
Published: 13 June 2025
View article titled, Abstract P2-10-19: A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
Journal Articles

Abstract PS18-06: Primary results and the transcriptomic analysis of PELOPS, a randomized phase II study of neoadjuvant palbociclib with or without endocrine therapy for breast cancer patients with invasive lobular carcinoma or invasive ductal carcinoma

Free
Rinath Jeselsohn, Douglas Russo, Qingchun Jin, Patrick Kurnia, Jorge Gomez Tejeda, Kavya Prasad, Shira Sherman, Michelle K Demeo, Ying Huang, Jane Brock, Deborah A. Dillon, Tari A. King, Denise Yardley, Ingrid A Mayer, William F Symmans, Chip Stewart, Eric Winer, Nabihah Tayob, Gaddy Getz, Sara M Tolaney, Otto Metzger
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS18-06.
https://doi.org/10.1158/1557-3265.SABCS24-PS18-06
Published: 13 June 2025
View article titled, Abstract PS18-06: Primary results and the transcriptomic analysis of PELOPS, a randomized phase II study of neoadjuvant palbociclib with or without endocrine therapy for breast cancer patients with invasive lobular carcinoma or invasive ductal carcinoma
Journal Articles

Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma

Open Access
Abdullah A. Osman, Emre Arslan, Mason Bartels, Chieko Michikawa, Antje Lindemann, Katarzyna Tomczak, Wangjie Yu, Vlad Sandulache, Wencai Ma, Li Shen, Jing Wang, Anand K. Singh, Mitchell J. Frederick, Nakia D. Spencer, Jeffery Kovacs, Timothy Heffernan, William F. Symmans, Kunal Rai, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1344–1359.
https://doi.org/10.1158/1078-0432.CCR-22-2747
Published: 03 April 2023
View article titled, Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Open the PDF for Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer

Free
Funda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, Aysegul Sahin, Emily Tarco, Selin Carkaci, Beatriz E. Adrada, Gopal Singh, Kim-Anh Do, Zerzhinski M. Garces, Elizabeth Mittendorf, Gildy Babiera, Isabelle Bedrosian, Rosa Hwang, Savitri Krishnamurthy, William F. Symmans, Ana Maria Gonzalez-Angulo, Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3870–3883.
https://doi.org/10.1158/1078-0432.CCR-13-1507
Published: 14 July 2014
View article titled, Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer
Open the PDF for Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

Free
Aman U. Buzdar, Vicente Valero, Nuhad K. Ibrahim, Deborah Francis, Kristine R. Broglio, Richard L. Theriault, Lajos Pusztai, Marjorie C. Green, Sonja E. Singletary, Kelly K. Hunt, Aysegul A. Sahin, Francisco Esteva, William F. Symmans, Michael S. Ewer, Thomas A. Buchholz, Gabriel N. Hortobagyi
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (1): 228–233.
https://doi.org/10.1158/1078-0432.CCR-06-1345
Published: 02 January 2007
View article titled, Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen
Open the PDF for Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen in another window